Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 341

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Open access
for the SAKK and the German CML Study Group, Hehlmann, R, Lauseker, M, Saußele, S, Pfirrmann, M, Krause, S, Kolb, H J, Neubauer, A, Hossfeld, D K, Nerl, C, Gratwohl, A, Baerlocher, G M, Heim, D, Brümmendorf, T H, Fabarius, A, Haferlach, C, Schlegelberger, B, Müller, M C, Jeromin, S, Proetel, U, Kohlbrenner, K, Voskanyan, A, Rinaldetti, S, Seifarth, W, Spieß, B, Balleisen, L, Goebeler, M C, Hänel, M, Ho, A, Dengler, J, Falge, C, Kanz, L, Kremers, S, Burchert, A, Kneba, M, Stegelmann, F, Köhne, C A, Lindemann, H W, Waller, C F, Pfreundschuh, M, Spiekermann, K, Berdel, W E, Müller, L, Edinger, M, Mayer, J, Beelen, D W, Bentz, M, Link, H, Hertenstein, B, Fuchs, R, Wernli, M, Schlegel, F, Schlag, R, de Wit, M, Trümper, L, Hebart, H, Hahn, M, Thomalla, J, Scheid, C, Schafhausen, P, Verbeek, W, Eckart, M J, Gassmann, W, Pezzutto, A, Schenk, M, Brossart, P, Geer, T, Bildat, S, Schäfer, E, Hochhaus, A, Hasford, J·2017·Leukemia
DOI 10.1038/leu.2017.253
Open this paper in CoChat — free account

Abstract

Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytarabine (n=158) or using IM after IFN-failure (n=128). From July 2002 to March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study was powered to detect a survival difference of 5% at 5 years. After a median observation time of 9.5 years, 10-year overall survival was 82%, 10-year progression-free survival was 80% and 10-year relative survival was 92%. Survival between IM400 mg and any experimental arm was not different. In a multivariate analysis, risk group, major-route chromosomal aberrations, comorbidities, smoking and treatment center (academic vs other) influenced survival significantly, but not any form of treatment optimization. Patients reaching the molecular response milestones at 3, 6 and 12 months had a significant survival advantage. For responders, monotherapy with IM400 mg provides a close to normal life expectancy independent of the time to response. Survival is more determined by patients' and disease factors than by initial treatment selection. Although improvements are also needed for refractory disease, more life-time can currently be gained by carefully addressing non-CML determinants of survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2017.253

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 341

Metadata

Authors
for the SAKK and the German CML Study Group, Hehlmann, R., Lauseker, M., Saußele, S., Pfirrmann, M., Krause, S., Kolb, H. J., Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., Baerlocher, G. M., Heim, D., Brümmendorf, T. H., Fabarius, A., Haferlach, C., Schlegelberger, B., Müller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Voskanyan, A., Rinaldetti, S., Seifarth, W., Spieß, B., Balleisen, L., Goebeler, M. C., Hänel, M., Ho, A., Dengler, J., Falge, C., Kanz, L., Kremers, S., Burchert, A., Kneba, M., Stegelmann, F., Köhne, C. A., Lindemann, H. W., Waller, C. F., Pfreundschuh, M., Spiekermann, K., Berdel, W. E., Müller, L., Edinger, M., Mayer, J., Beelen, D. W., Bentz, M., Link, H., Hertenstein, B., Fuchs, R., Wernli, M., Schlegel, F., Schlag, R., de Wit, M., Trümper, L., Hebart, H., Hahn, M., Thomalla, J., Scheid, C., Schafhausen, P., Verbeek, W., Eckart, M. J., Gassmann, W., Pezzutto, A., Schenk, M., Brossart, P., Geer, T., Bildat, S., Schäfer, E., Hochhaus, A., & Hasford, J.
Venue
Leukemia
Publisher
Springer Science and Business Media LLC
Published
2017-08-14
Volume
31
Issue
11
Pages
2398-2406
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
DOI
10.1038/leu.2017.253
OpenAlex
W2750206713
Cited by
341
References
38
FWCI
19.36
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. https://app.cochat.ai/papers/10.1038/leu.2017.253
The paper
for the SAKK and the German CML Study Group, Hehlmann, R., Lauseker, M., Saußele, S., Pfirrmann, M., Krause, S., Kolb, H. J., Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., Baerlocher, G. M., Heim, D., Brümmendorf, T. H., Fabarius, A., Haferlach, C., Schlegelberger, B., Müller, M. C., Jeromin, S., . . . Hasford, J. (2017). Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. https://doi.org/10.1038/leu.2017.253

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.